2021
Meta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials
Nasir M, Li F, Courley S, Olten B, Bloch MH. Meta-Analysis: Pediatric Placebo Response in Depression Trials Does Not Replicate in Anxiety and Obsessive-Compulsive Disorder Trials. Journal Of Child And Adolescent Psychopharmacology 2021, 31: 670-684. PMID: 34558984, DOI: 10.1089/cap.2021.0030.Peer-Reviewed Original ResearchConceptsPlacebo response ratesObsessive-compulsive disorderPlacebo responseDepression trialsResponse ratePlacebo improvementSymptom improvementAntidepressant trialsStratified subgroup analysisRandom-effects modelPediatric populationSubgroup analysisStudy visitNumber of subjectsPsychopharmacological trialsPubMed searchDifferent indicationsDiagnostic indicationsMean differenceAnxiety disordersTrialsDisordersPediatric anxietyPredictorsPossible correlates
2019
Meta-analysis of placebo group dropout in adult antidepressant trials
Li F, Nasir M, Olten B, Bloch MH. Meta-analysis of placebo group dropout in adult antidepressant trials. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2019, 98: 109777. PMID: 31697973, DOI: 10.1016/j.pnpbp.2019.109777.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderPlacebo leadAntidepressant trialsDiagnostic indicationsPlacebo-controlled trialStratified subgroup analysisBaseline illness severityMore study visitsDropout rateOverall dropout rateFreeman-Tukey transformationLonger trial durationEarlier publication yearPlacebo groupIllness severitySubgroup analysisDepressive disorderStudy visitMeta-AnalysisTrial durationAnxiety disordersTrialsEfficiency of trialsSubject burdenDisordersEfficacy and Tolerability of Pharmacotherapy for Pediatric Anxiety Disorders: A Network Meta-Analysis.
Dobson ET, Bloch MH, Strawn JR. Efficacy and Tolerability of Pharmacotherapy for Pediatric Anxiety Disorders: A Network Meta-Analysis. The Journal Of Clinical Psychiatry 2019, 80 PMID: 30753760, DOI: 10.4088/jcp.17r12064.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsTolerability of pharmacotherapyTreatment-emergent suicidalityMedication classesTreatment responsePediatric anxiety disordersAnxiety disordersReuptake inhibitorsTolerability of medicationsPlacebo-controlled trialSerotonin reuptake inhibitorsNetwork Meta-AnalysisRisk of biasWeb of ScienceCause discontinuationGeMTC packageSuicidality dataCochrane riskMultiple medicationsBias toolPediatric patientsMedication trialsAgonist treatmentCochrane Database
2018
Systematic review and meta‐analysis: Dose–response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski E, Johnson JA, Nasir M, Müller‐Vahl K, Bloch MH. Systematic review and meta‐analysis: Dose–response curve of SSRIs and SNRIs in anxiety disorders. Depression And Anxiety 2018, 36: 198-212. PMID: 30479005, DOI: 10.1002/da.22854.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsGreater treatment benefitHigh dosesTreatment responseAnxiety disordersReuptake inhibitorsSymptom improvementTreatment benefitPharmacological agentsRandomized placebo-controlled clinical trialSSRIs/serotonin-norepinephrine reuptake inhibitorsPlacebo-controlled clinical trialIndividual pharmacological agentsCochrane Central RegisterNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsOverall symptom improvementGreater symptom improvementDose-response curveLinear mixed model analysisCentral RegisterMedication classesAdult patientsControlled Trials
2017
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta K, Beyer C, Johnson JA, Bloch MH. Meta-analysis: Risk of dry mouth with second generation antidepressants. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2017, 84: 282-293. PMID: 29274375, DOI: 10.1016/j.pnpbp.2017.12.012.Peer-Reviewed Original ResearchConceptsDry mouthSecond-generation antidepressantsGreater riskAntidepressant agentsGeneration antidepressantsPlacebo-controlled trialPooled risk ratioStratified subgroup analysisReceptor affinity profileSNRI classMedication classesAntidepressant medicationAtypical antidepressantsRisk ratioSubgroup analysisDepressive disorderSTUDY SELECTIONPubMed searchDATA SOURCESSNRIsDiagnostic indicationsSSRIsAntidepressantsAnxiety diagnosesAnxiety disordersMonotherapy Insufficient in Severe Anxiety? Predictors and Moderators in the Child/Adolescent Anxiety Multimodal Study
Taylor JH, Lebowitz ER, Jakubovski E, Coughlin CG, Silverman WK, Bloch MH. Monotherapy Insufficient in Severe Anxiety? Predictors and Moderators in the Child/Adolescent Anxiety Multimodal Study. Journal Of Clinical Child & Adolescent Psychology 2017, 47: 266-281. PMID: 28956620, PMCID: PMC6191182, DOI: 10.1080/15374416.2017.1371028.Peer-Reviewed Original ResearchConceptsChild/Adolescent Anxiety Multimodal StudyCognitive behavioral therapyModerators of outcomeSevere anxietyCombination of CBTIndependent evaluator ratingsMultimodal studyParent-rated anxietySeparation anxiety disorderMain effect findingsObsessive-compulsive disorderAnxious youthSocial anxietyChild anxietyBehavioral therapyAnxiety severityPill placeboAnxiety disordersEvaluators' ratingsAnxietyModeratorSocioeconomic statusLow socioeconomic statusYouthEffect findingsKetamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial
Taylor JH, Landeros-Weisenberger A, Coughlin C, Mulqueen J, Johnson JA, Gabriel D, Reed MO, Jakubovski E, Bloch MH. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology 2017, 43: 325-333. PMID: 28849779, PMCID: PMC5729569, DOI: 10.1038/npp.2017.194.Peer-Reviewed Original ResearchConceptsLiebowitz Social Anxiety ScaleSocial anxiety disorderAnxiety disordersSocial Anxiety ScaleSelf-reported anxietySocial phobia symptomsRatings of anxietyPotent N-methyl-d-aspartate receptor antagonistPhobia symptomsAnxiety symptomsAnxiety ScaleImpact of ketamineInitial evidenceAnxietyTreatment respondersVAS anxietyPlacebo-controlled crossover trialRatingsDisordersLinear mixed modelsPrior studiesConcept trialInadequate symptom reliefRandom orderMixed modelsThe efficacy of benzodiazepines as acute anxiolytics in children: A meta‐analysis
Kuang H, Johnson JA, Mulqueen JM, Bloch MH. The efficacy of benzodiazepines as acute anxiolytics in children: A meta‐analysis. Depression And Anxiety 2017, 34: 888-896. PMID: 28504861, PMCID: PMC5629100, DOI: 10.1002/da.22643.Peer-Reviewed Original ResearchConceptsEfficacy of benzodiazepinesPediatric patientsAnxiety disordersTolerability of benzodiazepinesRoom proceduresCurrent practice guidelinesStandardized mean differenceFunnel plot asymmetryOperating room proceduresProcedural settingsPediatric anxiety disordersTolerability analysisAcute managementBenzodiazepine treatmentStratified subgroupsPractice guidelinesControl groupAcute anxiolyticPublication biasAnxiolyticsBenzodiazepinesMean differencePatientsSpecific agentsAnxiety levels
2015
Family accommodation in obsessive-compulsive and anxiety disorders: a five-year update
Lebowitz ER, Panza KE, Bloch MH. Family accommodation in obsessive-compulsive and anxiety disorders: a five-year update. Expert Review Of Neurotherapeutics 2015, 16: 45-53. PMID: 26613396, PMCID: PMC4895189, DOI: 10.1586/14737175.2016.1126181.Peer-Reviewed Original ResearchConceptsFamily accommodationObsessive-compulsive disorderAnxiety disordersNeurobiological underpinningsSevere psychopathologySynthesis of findingsPsychiatric disordersDisordersPsychopathologyMain findingsDistressAccommodationFindingsUnderpinningsEnglish language papersFive-Year UpdatePsycINFOTherapeutic goalsIndividualsLanguage papersResearchAnxiety Disorder-Specific Predictors of Treatment Outcome in the Coordinated Anxiety Learning and Management (CALM) Trial
Jakubovski E, Bloch MH. Anxiety Disorder-Specific Predictors of Treatment Outcome in the Coordinated Anxiety Learning and Management (CALM) Trial. Psychiatric Quarterly 2015, 87: 445-464. PMID: 26563229, DOI: 10.1007/s11126-015-9399-6.Peer-Reviewed Original ResearchConceptsSocial anxiety disorderAnxiety disordersCoordinated Anxiety LearningAnxiety LearningPost-traumatic stress disorderSelf-efficacy expectanciesPositive treatment expectanciesGeneralized anxiety disorderTreatment outcomesStress disorderTreatment expectanciesSpecific treatment needsSocial supportPanic disorderDisordersLearningSocioeconomic statusPredictorsPredictors of anxiety recurrence in the Coordinated Anxiety Learning and Management (CALM) trial
Taylor JH, Jakubovski E, Bloch MH. Predictors of anxiety recurrence in the Coordinated Anxiety Learning and Management (CALM) trial. Journal Of Psychiatric Research 2015, 65: 154-165. PMID: 25896121, PMCID: PMC4492801, DOI: 10.1016/j.jpsychires.2015.03.020.Peer-Reviewed Original ResearchConceptsCoordinated Anxiety LearningAnxiety recurrenceAnxiety LearningAnxiety Sensitivity Index scoreUsual careCognitive behavioral therapyRelapse prevention programAnxiety remissionBehavioral therapyAnxiety disordersMultivariable logistic regression modelResidual anxietyCollaborative care interventionPrimary care clinicsPrimary care settingRisk of recurrenceComorbid depressionManagement trialsReceiver Operating CharacteristicLogistic regression modelsMonth 6Care clinicsPrevention programsPrognostic subgroupsCare interventions
2014
Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial.
Kelly JM, Jakubovski E, Bloch MH. Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial. The Journal Of Clinical Psychiatry 2014, 76: 267-78. PMID: 25562579, PMCID: PMC4930076, DOI: 10.4088/jcp.13m08922.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic Uptake InhibitorsAdultAgedAnti-Anxiety AgentsAnxiety DisordersBenzodiazepinesCognitive Behavioral TherapyCombined Modality TherapyDepressive Disorder, MajorFemaleHumansMaleMiddle AgedOutcome Assessment, Health CarePanic DisorderPhobic DisordersPrognosisRemission InductionSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexSex FactorsSocial ClassSocial SupportStress Disorders, Post-TraumaticYoung AdultConceptsLow socioeconomic statusCoordinated Anxiety LearningUsual careGeneralized anxiety disorderPosttraumatic stress disorderAnxiety disordersBaseline characteristicsPatient characteristicsPrognostic subgroupsAnxiety LearningSocioeconomic statusBaseline patient characteristicsCollaborative care interventionPrimary care settingPoor treatment outcomesCommunity treatment centersDSM-IV criteriaManagement trialsCognitive behavioral therapyLimited social supportExploratory moderator analysesMost patientsRemission criteriaComorbid depressionPrognostic outcomesA meta-analysis of computerized cognitive-behavioral therapy for the treatment of DSM-5 anxiety disorders.
Adelman CB, Panza KE, Bartley CA, Bontempo A, Bloch MH. A meta-analysis of computerized cognitive-behavioral therapy for the treatment of DSM-5 anxiety disorders. The Journal Of Clinical Psychiatry 2014, 75: e695-704. PMID: 25093485, DOI: 10.4088/jcp.13r08894.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyPerson cognitive-behavioural therapyComputerized cognitive behavioral therapyAnxiety disordersComputerized CBTNon-PTSD anxiety disordersCompletion of treatmentTreatment gainsStandardized mean differenceDSM-5 anxiety disordersGreater symptom reductionWait-list controlSpecific anxiety disordersFixed-effects modelClinical outcomesClinical comorbiditiesEfficacious interventionsSymptom reductionReal-world settingGreater efficacyMeta-AnalysisCBT treatmentMean differenceDisordersAnxiety symptoms
2013
Age and Gender Correlates of Pulling in Pediatric Trichotillomania
Panza KE, Pittenger C, Bloch MH. Age and Gender Correlates of Pulling in Pediatric Trichotillomania. Journal Of The American Academy Of Child & Adolescent Psychiatry 2013, 52: 241-249. PMID: 23452681, PMCID: PMC3745006, DOI: 10.1016/j.jaac.2012.12.019.Peer-Reviewed Original ResearchConceptsFrequent urgesCommon comorbid conditionsPediatric trichotillomaniaProspective longitudinal studyType of treatmentCross-sectional findingsClinical characteristicsComorbid conditionsStructured rating scaleTreatment trialsComorbid depressionRating ScaleAnxiety disordersOlder childrenTrichotillomaniaDecreased abilityLongitudinal studyMale participantsAgeChildrenGreater distressFemale participantsLower ratesSymptomsGender correlates
2011
Pharmacological Treatment for Phobias and Anxiety Disorders
Bloch M, McGuire J. Pharmacological Treatment for Phobias and Anxiety Disorders. 2011, 339-354. DOI: 10.1007/978-1-4419-7784-7_23.Peer-Reviewed Original Research
2008
Riluzole in the Treatment of Mood and Anxiety Disorders
Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the Treatment of Mood and Anxiety Disorders. CNS Drugs 2008, 22: 761-786. PMID: 18698875, DOI: 10.2165/00023210-200822090-00004.Peer-Reviewed Original ResearchConceptsTreatment of moodAnxiety disordersMultiple molecular actionsOpen-label trialPlacebo-controlled trialAmino acid neurotransmissionCommon adverse effectsLiver function testsAmyotrophic lateral sclerosisVoltage-gated sodium channelsBorderline personality disorderSelf-injurious behaviorStandard therapyIll patientsBipolar depressionFunction testsObsessive-compulsive disorderCase reportGlutamatergic neurotransmissionGlutamate levelsExtracellular glutamateClinical consequencesLateral sclerosisAstrocytic uptakeRiluzole